Clinical Trials

AbbVie reported data from a pair of Phase III studies showing that Skyrizi (risankizumab) led to significantly more psoriatic arthritis patients achieving the primary endpoint of at least 20% improvement on American College of Rheumatology (ACR20) criteria than placebo...

Vir Biotechnology, Inc. announced that the first patient has been dosed in a new sub-trial of the National Institutes of Health’s (NIH) Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) Program Phase 3 clinical trial. This trial is designed to...

GCSA launched with a commitment to increase clinical research and trial capacity and quality in the UK as well as Globally. This will be achieved through the introduction of an industry leading standard for improving, maintaining and accrediting clinical...

Russia’s Sputnik V vaccine has demonstrated an efficacy of over 90 percent, according to the Gamaleya Center and the Russian Direct Investment Fund. “Evaluation of efficacy was carried out among volunteers 21 days after receiving the first dose of the...

Roche announced that it has launched a high-throughput SARS-CoV-2 antigen test as an aid in the diagnosis of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infections, in markets accepting the CE Mark. Roche has also filed for Emergency Use...

Sanofi and GSK announce a delay in their adjuvanted recombinant protein-based COVID-19 vaccine program to improve immune response in older adults. Phase 1/2 study interim results showed an immune response comparable to patients who recovered from COVID-19 in adults...

Incyte announced that the Phase 3 RUXCOVID study evaluating the safety and efficacy of ruxolitinib (Jakafi®), a JAK1/JAK2 inhibitor, plus standard-of-care (SoC) as a treatment for patients 12 years and older with COVID-19 associated cytokine storm did not meet...